@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix ns1: <https://w3id.org/np/o/ntemplate/> .
@prefix this: <http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps> .
@prefix sub: <http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix npx: <http://purl.org/nanopub/x/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix nkg: <https://w3id.org/um/neurodkg/> .
@prefix prov: <http://www.w3.org/ns/prov#> .

<http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps> a np:Nanopublication;
  np:hasAssertion sub:assertion;
  np:hasProvenance sub:provenance;
  np:hasPublicationInfo sub:pubinfo;
  dct:created "2021-09-13T13:11:54.555+02:00"^^xsd:dateTime;
  dct:creator orcid:0000-0002-7641-6446;
  npx:supersedes <http://purl.org/np/RA5i91jVBRKHpwDOPIiWGzt3c3Rs8wAqKRXxOYhegMxOI>;
  prov:generatedAtTime "2021-08-24T15:53:47.29208";
  prov:wasAttributedTo orcid:0000-0002-7641-6446;
  ns1:wasCreatedFromProvenanceTemplate <http://purl.org/np/RAcm8OurwUk15WOgBM9wySo-T3a5h6as4K8YR5MBrrxUc>;
  ns1:wasCreatedFromPubinfoTemplate <http://purl.org/np/RA2vCBXZf-icEcVRGhulJXugTGxpsV5yVr9yqCI1bQh4A>,
    <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>, <http://purl.org/np/RAjpBMlw3owYhJUBo3DtsuDlXsNAJ8cnGeWAutDVjuAuI>;
  ns1:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .

<http://purl.obolibrary.org/obo/MONDO_0024612> biolink:category biolink:Disease .

sub:association a rdf:Statement;
  rdf:object <http://purl.obolibrary.org/obo/MONDO_0024612>;
  rdf:predicate biolink:treats;
  rdf:subject <https://identifiers.org/DRUGBANK:DB01267>;
  rdfs:label "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)";
  biolink:provided_by <https://w3id.org/um/NeuroDKG>;
  biolink:publications <https://pubmed.ncbi.nlm.nih.gov/31096228>;
  biolink:relation nkg:OffLabelIndication .

<https://identifiers.org/DRUGBANK:DB01267> biolink:category biolink:Drug .

sub:assertion prov:generatedAtTime "2021-08-24T15:53:47.29208" .

sub:sig npx:hasAlgorithm "RSA";
  npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
  npx:hasSignature "S36lxqMhE/il6hZ0x3opIf+BSGkgmrLS42CchAvMGjt03GhGQT20XdwHEBLps4EIevPEFYR3JCJttJowJ3HtWv4hSQ5sLxtGzcLW+7AD86Mrp/G3xGClqtMyQmf0MU7glLc83g8n8nenTaQOX37aaSuUPH+I3cZQJ1cSqTfX5ss=";
  npx:hasSignatureTarget <http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps> .